(CEL) |
| 0 (0%) 08-30 21:22 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 344.95 |
| Resistance 1: | 295.33 |
| Pivot price: | 282.95 |
| Support 1: | 279.06 |
| Support 2: | 269.00 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 7.460 |
| Book Value | 35.870 |
| PEG Ratio | 2.90 |
| Gross Profit | 26.576 |
| Profit Margin (%) | 12.57 |
| Operating Margin (%) | 18.52 |
| Return on Assets (ttm) | 7.2 |
| Return on Equity (ttm) | 22.0 |
Company news
Sat, 29 Aug 2026
Bayer 04 Leverkusen vs Celje Box Score - September 16, 2026 - The Athletic - The New York Times
Fri, 28 Aug 2026
Beyond CRS and ICANS: Managing the Delayed Toxicities of Cilta-cel - Pharmacy Times
Thu, 27 Aug 2026
Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy - Nature
Wed, 26 Aug 2026
Immatics adds $150M ahead of anzu-cel readout - European Biotechnology Magazine
Tue, 25 Aug 2026
Cellectis: 'Hold' Lasme-Cel Q4 2026 Catalyst And Eti-Cel Backup Candidate (NASDAQ:CLLS) - Seeking Alpha
Thu, 20 Aug 2026
Miv-cel Earns RMAT Designation for Progressive Multiple Sclerosis - CGTLive®
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
